Introduced in House
Sponsored by Brian Babin (R, TX-36)
- INTRODUCED
- COMMITTEEJun 20, 2025
- PASSED HOUSE
- SENATE
- LAW
In committee. Latest action on Jun 20, 2025: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. It has 2 cosponsors and 3 recorded actions, and 1 organizations cited it in Q4 2025 lobbying disclosures.
Recent actions
3 totalIntroduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Reported lobbying
| Organization | Filed by | Total Q4 2025 lobbying |
|---|---|---|
| Kaneka Pharma America | King & Spalding | $40,000 |
These totals are not spending on this bill. Lobbying is reported per filing, not per issue — each figure is everything the organization reported for the period, across every bill and agency it named. Read it as scale of presence.
Latest activity
No recent bill events yet. The complete action history is above.
